Treatment for dopaminergic disorders

Abstract

The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Ca v 1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).

We claim: 
     
         1 . A method of treatment for dopaminergic disorders comprising: administering to a subject having a dopaminergic disorder: i) a first compound that inhibits a voltage-gated calcium channel of the type Ca v 1.3, and ii) a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor. 
     
     
         2 . The method of  claim 1 , wherein said first compound comprises a dihydropyridine calcium channel blocker. 
     
     
         3 . The method of  claim 1 , wherein said first compound comprises isradipine and said second compound comprises rasagiline or a rasagiline derivative. 
     
     
         4 . The method of  claim 1 , wherein said administering said first and second compounds to said subject is repeated on multiple days. 
     
     
         5 . The method of  claim 4 , wherein no more than 9 mg of said first compound is administered to said subject on any given day. 
     
     
         6 . The method of  claim 5 , wherein said first compound comprises isradipine. 
     
     
         7 . The method of  claim 5 , wherein said second compound comprises rasagiline or a rasagiline derivative. 
     
     
         8 . The method of  claim 4 , wherein said first compound comprises isradipine, wherein said second compound comprises rasagiline or a rasagiline derivative, wherein between about 0.5 mg and about 5.0 mg of said isradipine is administered per day, and wherein about 0.5 mg and about 2.0 mg of said rasagiline or rasagiline derivative is administered per day. 
     
     
         9 . The method of  claim 1 , wherein said first compound is in a controlled release formulation. 
     
     
         10 . A composition comprising: i) a first compound that inhibits a voltage-gated calcium channel of the type Ca v 1.3, and ii) a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor. 
     
     
         11 . The composition of  claim 10 , wherein said first compound comprises a dihydropyridine calcium channel blocker. 
     
     
         12 . The composition of  claim 10 , wherein said first compound comprises isradipine and said second compound comprises rasagiline or a rasagiline derivative. 
     
     
         13 . The composition of  claim 10 , wherein said first composition contains no more than 9 mg of said first compound. 
     
     
         14 . The composition of  claim 13 , wherein said first compound comprises isradipine. 
     
     
         15 . The composition of  claim 13 , wherein said second compound comprises rasagiline or a rasagiline derivative. 
     
     
         16 . The composition of  claim 10 , wherein said first compound comprises isradipine, wherein said second compound comprises rasagiline or a rasagiline derivative, wherein said composition contains between about 0.5 mg and about 5.0 mg of said isradipine and between about 0.5 mg and about 2.0 mg of said rasagiline or rasagiline derivative. 
     
     
         17 . The composition of  claim 10 , wherein said first compound is in a controlled release formulation within said composition. 
     
     
         18 . A kit comprising:
 i) a first composition comprising a first compound that inhibits a voltage-gated calcium channel of the type Ca v 1.3, and   ii) a second composition comprising a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor.   
     
     
         19 . The kit of  claim 18 , wherein said first compound comprises isradipine and said second compound comprises rasagiline or a rasagiline derivative. 
     
     
         20 . The kit of  claim 18 , wherein said first composition contains no more than 9 mg of said first compound.